Incyte-Merck trial failure deals a blow to cancer immunotherapy, but researchers remain hopeful – CNBC
CNBC |
Incyte-Merck trial failure deals a blow to cancer immunotherapy, but researchers remain hopeful
CNBC The future of cancer immunotherapy looks promising, but it suffered a major setback on Friday. Incyte announced that its trial drug epacadostat did not help melanoma patients, and the company is halting the study altogether. Epacadostat was supposed to … Melanoma trial failure deals heavy blow to immunotherapy hopes Incyte stock drops after melanoma therapy drug testing fails Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda |
